EUCTR2012-001260-29-IT
Active, not recruiting
Not Applicable
Identification of predictive plasma Biomarkers and use of a high dosage statin during a procedure of Parrossistic Atrial Fibrillation pharmacological Cardioversion - 2012-CARDAF
FONDAZIONE ISTITUTO SAN RAFFAELE-G.GIGLIO0 sitesMarch 29, 2012
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- FONDAZIONE ISTITUTO SAN RAFFAELE-G.GIGLIO
- Status
- Active, not recruiting
- Last Updated
- 13 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) patient between 18 and 75 years of age 2\) patient able to understand the study aims and methods, to sign the informed consents relative to the part of the study he is willing to participate 3\) patient showing the medical conditions that make a cardioversion procedure mandatory 4\) patient whose clinical conditions allow to delay the cardioversion procedure for the time required to enroll the patients in the study (stable patient, that is not feeling extreme pain or anxiety for the condition related to the current episode of atrial fibrillation)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 120
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 120
Exclusion Criteria
- •1\) hemodynamically unstable patient or bearing comorbidities precluding the possibility to complete the procedures of the study. 2\) patient with diagnosis of class III\-IV heart failure according to the NYHA classification 3\) patients assuming chronically a statin at maximum dosage. 4\) patient without hystory of statin intollerance characterized by: statin related myalgia and/or increase of specific enzymes elevation (CK \> 2xULN; AST or ALT \> 3x ULN) 5\) patient assuming oral anticoagulant therapy 6\) patient with affections determining intestinal malabsorption as: gastro\-ileal by pass, gastric banding, other causes 7\) patient with chronic kidney disease stage IV or more according to the NFK classification (calculated Glomerular filtrate rate \< 30 ml/min) 8\) patient with altered consciousness level, and/or a mental disease not adequately controlled by drug therapy.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Terminated
Not Applicable
Plasma Biomarkers P-DAC, V1Pancreatic Ductal AdenocarcinomaNCT02050997Cancer Trials Ireland169
Completed
Not Applicable
Elucidation of biomarkers to predict the presence of coronary vulnerable plaqueJPRN-UMIN000009806agasaki University Graduate School of Biomedical Sciences200
Recruiting
Not Applicable
Identification of biomarkers for diagnosis and prognosis in the patients with obstructive sleep apneaobstructive sleep apneaJPRN-UMIN000021503Osaka university graduate School of medicine The department of geriatric and general medicine200
Completed
Not Applicable
Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinomaC25Malignant neoplasm of pancreasDRKS00023929Allgemein- und Viszeralchirurgie Uniklinik Freiburg14
Completed
Not Applicable
Validation of New Biomarkers for Monitoring P. falciparum Reduced susceptibility/Tolerance or Resistance to Artemisinin Derivatives and Partner DrugsMalariaPACTR201508001191898EDCTP